You just read:

Galmed's 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study

News provided by

Galmed Pharmaceuticals Ltd.

12 Jun, 2018, 12:52 BST